Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccine with Adjuvants in Advanced Melanoma
NCT00003362Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 1998
- Primary completion
- Feb 2001
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gp100 peptide + tyrosinase peptide in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Started May 1998; status: completed.
02
Drugs
gp100 peptide + tyrosinase peptide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00003362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003362.